Systems pharmacogenomics - gene, disease, drug and placebo interactions: a case study in COMT
Systems pharmacogenomics - gene, disease, drug and placebo interactions: a case study in COMT
复制标题
DOI：
10.2217/pgs-2019-0001
复制
发表时间：
2019-05-01
期刊：
影响因子：
2.1
通讯作者：
Kaptchuk, Ted J.
中科院分区：
文献类型：
--
作者：
Hall, Kathryn T.;Loscalzo, Joseph;Kaptchuk, Ted J.
在双盲、随机对照试验的方法中，疾病、药物和用作比较的安慰剂有着千丝万缕的联系。尽管如此，药物基因组学（基于遗传底物研究个体如何对药物做出反应）主要关注基因和药物之间的联系，而基因和疾病之间的联系经常被忽视，基因和安慰剂之间的联系在很大程度上被忽视。在此，我们使用儿茶酚-O-甲基转移酶的例子来检验基因可以作为跨系统调节过程的药物基因组中心的假设，如果在无性对照试验中受到干扰，可能会对药物和安慰剂反应产生主要和组合影响。
Disease, drugs and the placebos used as comparators are inextricably linked in the methodology of the double-blind, randomized controlled trial. Nonetheless, pharmacogenomics, the study of how individuals respond to drugs based on genetic substrate, focuses primarily on the link between genes and drugs, while the link between genes and disease is often overlooked and the link between genes and placebos is largely ignored. Herein, we use the example of the enzyme catechol-O-methyltransferase to examine the hypothesis that genes can function as pharmacogenomic hubs across system-wide regulatory processes that, if perturbed in andomized controlled trials, can have primary and combinatorial effects on drug and placebo responses.